JAMA Pediatr

GLP-1 RAs improve metabolic outcomes in youth with obesity, T2DM

September 25, 2025

GLP-1 RAs offer a clinically meaningful option for improving metabolic outcomes in youth with obesity or T2DM. While GI side effects may limit long-term adherence, the overall safety profile supports their use as part of a comprehensive treatment strategy.

Study details: This systematic review and meta-analysis evaluated 18 randomized trials involving 1,402 participants aged 6 to 17 years with obesity, prediabetes, or T2DM. Researchers assessed the efficacy and safety of GLP-1 RAs compared with placebo, analyzing outcomes such as glycemic control, weight, BMI, and adverse events.

Results: GLP-1 RAs significantly improved HbA1c (−0.44%), fasting glucose (−9.92 mg/dL), body weight (−3.02 kg), BMI (−1.45), and systolic BP (−2.73 mm Hg). GI adverse events were more frequent in the treatment group, but rates of depression, suicidal ideation, and hepatobiliary disorders weren't significantly different from placebo.

Source:

Kotecha P, et al. (2025, September 15). JAMA Pediatr. Efficacy and Safety of GLP-1 RAs in Children and Adolescents With Obesity or Type 2 Diabetes: A Systematic Review and Meta-Analysis. https://pubmed.ncbi.nlm.nih.gov/40952752/